P300 substantially reprograms super-enhancers during hepatocellular carcinoma tumorigenesis; stimulates over-expression of super-enhancer-associated oncogenes such as MYC, MYCN and CCND1; and induces hepatocellular carcinoma cell proliferation in vitro and tumor progression in vivo66 (Table 1). Here, MYCN is linked to hepatocellular carcinoma.